; on behalf of the European Vasculitis Study Group Abstract Objective. The aim of this study was to evaluate whether chronic nasal carriage of Staphylococcus aureus (SA) is related to relapses in patients with newly diagnosed ANCA-associated vasculitis (AAV).
Introduction
Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) are characterized by the presence of ANCA against PR3 or MPO-ANCA [1, 2] . GPA and MPA constitute the two major diseases in the group of ANCAassociated vasculitides (AAV). A prominent clinical feature of GPA is destructive lesions in the nose and paranasal sinuses, which is absent in MPA [2, 3] . These nasal lesions are frequently associated with infections, and infections are related to relapses in GPA [4] . In GPA, chronic nasal carriage of Staphylococcus aureus (SA) has been associated with an increased relapse rate [5, 6] . Furthermore, nasal SA carriage has been reported to be more frequent in GPA patients compared with healthy controls [5, 7] . A randomized clinical trial (RCT) demonstrated that full-dose treatment with trimethoprim/sulfamethoxazole (T/S) was superior to placebo in preventing relapses in GPA patients in remission after therapy with CYC and CSs [8] . These findings have suggested a causal relationship between SA and relapses, but attempts to identify such pathogenic mechanisms have been hypothesis generating rather than demonstrating the exact mechanisms [912] .
In the first four European vasculitis study group therapeutic RCTs for AAV, monthly nasal swabs were collected in order to test whether patients with AAV had an increased propensity for nasal SA carriage at the time of diagnosis and whether nasal SA carriage was related to relapse (the SAVAS protocol). Given that relapses were most frequent in the nonrenal Wegener's granulomatosis treated alternatively with methotrexate (NORAM) (early systemic GPA) and cyclophosphamide versus azathioprine for remission in generalized vasculitis (CYCAZAREM) (generalized GPA and MPA) trials, these were chosen for the present study [13, 14] . In order to explore the possible pathogenic role of SA in GPA further, we studied whether nasal carriage of SA is directly related to relapses or rather that relapses are related to different clinical subsets of patients with different relapse rates. Previous studies have focused on the association between chronic nasal SA carriage (CNSAC) and relapse in patients with generalized GPA during stable remission [5] . The present study investigates the association between nasal SA carriage and relapses in AAV patients, focusing on the conditions found in newly diagnosed patients.
Methods

Study design
This SAVAS study is a prospective, multicentre survey based on the NORAM and CYCAZAREM RCTs conducted by the European vasculitis study group. NORAM explored whether MTX could replace CYC for treatment of early systemic AAV [13] . The treatment, including CSs, was given for 12 months. NORAM patients (n = 95) were mainly GPA (94%) with upper respiratory involvement (>90%) and serum creatinine <150 mmol/l, without critical organ manifestations. CYCAZAREM compared AZA with CYC for the maintenance of remission in generalized AAV after CYC and oral steroid-based induction therapy [14] . The treatment was given for 18 months. In the CYCAZAREM study (n = 155), 61% of patients were GPA and 39% MPA; 94% had renal involvement, with a mean glomerular filtration rate of 49 ml/min [14] .
Both studies were conducted according to the Declaration of Helsinki. Approval of ethics was obtained from each participating centre, and all patients gave their informed consent. This SAVAS study did not require additional ethical approval. The inclusion criteria and diagnostic nomenclature for both RCTs were based on clinical features consistent with vasculitis and a biopsy consistent with vasculitis and/or a positive ANCA test in accordance with the Chapel Hill Consensus Conference 2012 nomenclature [2] .
Patients
Of the initial sample of 250 patients included in the NORAM and CYCAZAREM studies, 200 were eligible for the present study (117, CYCAZAREM and 83, NORAM). Exclusion criteria were as follows: fewer than four nasal cultures, early withdrawal or death before remission or patient lost to follow-up.
T/S in prophylactic doses (960 mg three times a week) against pneumonia caused by Pneumocystis jirovecii was given according to local practice. Short courses of antibiotics to treat infections were permitted. Nasal swabs obtained during longer courses (i.e. >6 weeks) of antibiotics were disregarded in our analysis. Data on ANCA specificity were compiled from locally obtained results from IIF and solid phase assays, primarily ELISAs.
Nasal cultures and SA carrier status
According to the SAVAS protocol, nasal cultures were obtained at the time of diagnosis, then monthly and at relapse. The swabs were taken by firmly rotating a sterile cotton-tipped swab from the anterior nares and were incubated for 48 h at 35 C. The isolates were identified by typical appearance of colonies being coagulase positive by slide coagulase testing and the ability to cleave DNA.
The patient was defined as a chronic carrier of SA when 575% of at least four nasal cultures were positive [5] . When the patient was SA negative in all nasal cultures, the patient was defined as SA negative, whereas all other patients were classified as intermittent carriers.
Disease activity and relapses Disease activity was recorded every month for the first 6 months, once every 3 months thereafter, and at relapse using the BVAS [15] . Nasal disease activity was defined by BVAS items related to sino-nasal involvement being positively scored.
Remission was defined as the absence of new or worse clinical BVAS items. Relapse was defined on the basis of new and/or worse clinical disease activity on an intentionto-treat basis [13, 14] . In order to investigate whether nasal disease activity was correlated with SA carriage, data of relapses with nasal disease activity were collected separately.
Statistical analyses
CNSAC and relapse were the primary outcome variables. The effect of T/S on CNSAC and relapse were secondary outcome variables. The 2 test was used to test the categorical baseline characteristics of patients, and Student's independent samples t-test was used for continuous variables. The potential prognostic factors for CNSAC and relapse were age, level of disease severity (early systemic AAV vs generalized AAV), GPA diagnosis, PR3-ANCA positivity, nasal disease at entry, SA positivity at entry and T/S treatment. Univariate logistic regression analyses were performed to study the associations between CNSAC and relapse and for associations between prognostic factors and CNSAC and relapse. The interactions were tested including an appropriate interaction term in the model. The results are given as odds ratios (ORs) with 95% CIs.
The time to first relapse from remission was analysed using the KaplanMeier method. The univariate Cox proportional hazards model was then used to compare time without relapse. The results are given as hazard ratios (HRs) with 95% CIs.
Values of two-tailed P < 0.05 were considered significant. Analysis was performed using IBM SPSS Statistics for Windows (version 23.0; IBM Corp., Armonk, NY, USA).
Results
Baseline patient characteristics
The main characteristics of the study patients are given in Table 1 . The ANCA specificity and the diagnosis are given in Table 2 .
Nasal SA carriage
The total number of nasal swabs was 2467, with a median of 12 per patient (range 419). Only 24 of the 200 patients (12%) were chronic SA carriers. The distribution of nasal SA carrier status was not different in early systemic compared with generalized AAV (Table 3) . CNSAC in the different treatment arms of the two RCTs was also comparable: 10/99 (10.1%) with CYC (CYCAZAREM and NORAM), 5/42 (11.9%) with MTX (NORAM) and 9/59 (15.3%) with CYC followed by AZA (CYCAZAREM; P = 0.63).
As there were only two chronic SA carriers in the T/Streated group, we analysed the subgroup of non-T/S-treated patients separately. In the non-T/S-treated patients (n = 145), 22 (15.2%) were chronic SA carriers, 66 (45.5%) intermittent carriers and 57 (39.3%) non-carriers. In the T/S-treated patients (n = 55), the numbers were 2 (3.6%), 36 (65.5%) and 17 (30.9%), respectively. Thus, prophylactic T/S treatment was associated with a reduced risk of CNSAC (OR = 0.21, 95% CI: 0.05, 0.93; P = 0.04).
Chronic SA carriers were almost exclusively seen in GPA: 23/151 (15.2%) GPA patients vs 1/49 (2.0%) non-GPA patients (OR = 8.63, 95% CI: 1.13, 65.6; P = 0.04). Of GPA patients not treated with T/S, 21/109 (19.3%) were chronic SA carriers, whereas only 2/42 (4.8%) T/Streated GPA patients were chronic SA carriers (OR = 4.77, 95% CI: 1.07, 21.34; P = 0.04). CNSAC was associated with SA positivity at entry for all AAV patients. CNSAC was observed in 15/57 (26.3%) patients with a positive SA swab at entry vs 6/122 (4.9%) patients with a negative SA swab at entry (OR = 6.90, 95% CI: 2.51, 18.97; P < 0.001). Twenty-one patients did not have a swab at entry. The same applied for the 134 GPA patients with a swab at entry: 31.3% CNSAC in patients with a positive SA swab vs 6.7% with a negative swab (OR = 6.25, 95% CI: 2.20, 17.70; P = 0.001).
Relapses
Relapse occurred in 65/200 (32.5%) patients and was more common in early systemic (46/83, 55.4%) than in generalized AAV (19/117, 16.2%; OR = 6.41, 95% CI: 3.33, 12.34, P < 0.001), reflecting the relapse frequencies in the entire original RCT cohorts [13, 14] .
More relapses occurred in GPA than in non-GPA patients (39.1 vs 12.2%; OR = 4.60, 95% CI: 1.84, 11.47; P < 0.001), in PR3-ANCA-positive patients than in others (42.0 vs 8.8%; OR = 7.52, 95% CI: 2.83, 19.95; P < 0.001) and in those with nasal disease activity at entry than in patients without nasal disease (38.6 vs 20.6%; OR = 2.43, 95% CI: 1.23, 4.81; P = 0.01). In patients <50 years of age, relapses were more common than in older patients (30/70, 42.9% vs 35/130, 26.9%; OR = 2.04, 95% CI: 1.10, 3.75%; P = 0.02).
Nasal disease activity was present in 31/65 relapses and was more common in early systemic (25/78; 32.1%) than in generalized AAV (6/115, 5.2%; OR = 8.57, 95% CI: 3.32, 22.15; P < 0.001).
Relapses and nasal SA carriage related to disease severity For all AAV patients, relapse occurred in 10/24 (41.7%) patients with CNSAC (all GPA), in 32/102 (31.4%) patients who were intermittent SA carriers and in 23/74 (31.1%) non-carriers (P = 0.59; Fig. 1) , with no association between CNSAC and relapse (OR = 1.57, 95% CI: 0.66, 3.76; P = 0.31). However, there was a significant association between CNSAC and relapse in generalized AAV (OR = 4.64, 95% CI: 1.29, 16.67; P = 0.02), in contrast to early systemic AAV (OR = 0.52, 95% CI: 0.15, 1.81; P = 0.31). As chronic nasal carriage was almost exclusively seen in GPA, the 151 GPA patients were examined separately (Fig. 2) . In the 73 GPA patients with generalized disease, there was still an association between CNSAC and relapse (HR = 4.10, 95% CI: 1.37, 12.25; P = 0.01). In the 78 GPA patients with early systemic disease, there was also still no association (HR = 0.76, 95% CI: 0.30, 1.92; P = 0.56). However, in the NORAM study, immunosuppression was terminated at 12 months, resulting in a high relapse rate after month 12 [13] . To eliminate the effect of insufficient disease control after 12 months, time to the first relapse was analysed only for the first 12 months. During this period, CNSAC was associated with an increased relapse risk similar to the one seen for generalized disease (HR = 2.73, 95% CI: 0.95, 7.87; P = 0.06).
Relapses related to prophylactic T/S treatment
Although the use of T/S in prophylactic doses was not randomized in the RCTs, the clinical characteristics (sex, ANCA specificity, diagnosis, nasal disease activity or SA positivity at entry) of the treated and non-treated groups of patients did not differ (data not given).
In the T/S-treated patients, relapse occurred in 15/55 (27.3%) patients, and in the patients not treated with T/S, relapse was observed in 50/145 (34.5%) patients. The use of T/S was not associated with relapse risk (OR = 0.71, 95% CI: 0.36, 1.41; P = 0.33). The relationship between CNSAC and relapse was not influenced by T/S treatment either (P = 0.65 for interaction term). As in the patients treated with T/S, relapse was seen in 1/2 (50.0%) chronic SA carriers vs 14/53 (26.4%) non-carriers (OR = 2.79, 95% CI: 0.16, 47.6; P = 0.48), and in patients not treated with T/ S the figures were 9/22 (40.9%) chronic SA carriers vs 41/ 123 (33.3%) non-carriers (OR = 1.38, 95% CI: 0.44, 3.51; P = 0.49).
In GPA patients not treated with T/S (n = 109), 21 (19.3%) were chronic SA carriers. Relapses occurred in 44 (40.4%) patients, with 9 of these (20.5%) being chronic SA carriers.
Relapses and nasal SA carriage related to nasal disease activity
Relapse occurred more often in AAV patients with nasal disease activity at entry (51/132, 38.6%) than in patients without nasal disease activity at entry (14/68, 20.6%; OR = 2.43, 95% CI: 1.23, 4.81; P = 0.01). CNSAC tended also to The data are given according to disease severity, diagnosis, nasal SA carriage status (chronic or intermittent SA carrier or SA negative) and relapse status. Nasal means that relapse also included nasal activity. SA: Staphylococcus aureus.
www.rheumatology.oxfordjournals.org be found more frequently in patients with nasal disease at entry, as 20/132 (15.2%) patients with nasal disease activity and 4/68 (5.9%) patients without nasal disease activity were chronic SA carriers (OR = 2.86, 95% CI: 0.94, 8.73; P =0.07). These findings reflect the fact that non-GPA patients, rarely having nasal disease, have lower relapse rates (Fig. 1) . In GPA, nasal disease at entry was not associated with higher rates of relapse or CNSAC (OR = 1.35, 95% CI: 0.56, 3.25; P = 0.50 and OR = 1.54, 95% CI: 0.42, 5.60; P = 0.51, respectively).
Of the relapses with nasal activity occurring in GPA (n = 30), seven occurred in chronic SA carriers (7/23, 30.4%) and 23 in non-chronic SA carriers (23/123, 18.0%; P = 0.16; Fig. 1 ).
Discussion
In our study including 200 newly diagnosed AAV patients from two RCTs with prospectively collected data, we found that GPA patients, PR3-ANCA-positive patients and those with nasal disease activity at entry were more prone to relapse, confirming earlier studies [16, 17] . However, CNSAC was almost exclusively seen in GPA patients, with identical rates in early systemic and generalized GPA. Moreover, we found an increased risk of relapse in this subset of patients with CNSAC on immunosuppressive therapy in early systemic as well as generalized GPA. Finally, the use of T/S treatment in prophylactic doses did not influence the relapse risk, even though the rate of CNSAC was almost completely prevented.
From 1980 and thereafter, it was suggested that SA could trigger disease activity in GPA [37, 912] . Several mechanisms of how SA may promote this activation have been proposed; that is, through pro-inflammatory signalling and/or activation of the innate and adaptive immune system [10] . The initial report of a 7-fold increased risk of relapse due to CNSAC, reported in 1994 [5] , has not been confirmed, but others have found that CNSAC caused a 4.5-fold risk for relapse in limited GPA [6] , whereas Laudien et al. [7] showed only a trend for a higher relapse rate. A similar trend was also reported in a recent study from Norway [18] .
In healthy populations, 2030% of the persons followed longitudinally are persistently colonized with SA, whereas 50% are never or rarely colonized and 30% are colonized intermittently [19, 20] . A human colonization study showed that persistent SA carriers are different from intermittent carriers and non-carriers, as persistent carriers often reselect the autologous strain from the mixture of SA nasal re-inoculation and form more colony-forming units in cultures [21] . This indicates that there are only two types of nasal carriers, namely persistent carriers and others, and that CNSAC is a condition with distinct properties.
The rate of CNSAC of 15.2% in the present newly diagnosed GPA patients is somewhat lower than reported in the general population, possibly reflecting the use of T/S prophylaxis and also that antibiotics effective against SA used immediately before inclusion in the study may have been applied but not recorded. Furthermore, we have defined CNSAC as 575% positive swabs, in accordance with others [5, 8, 18] . This, however, differs from using a procedure with two nasal cultures within 1 week, which reliably predicts the CNSAC state when both qualitative and quantitative results are analysed [22] . Although an SApositive first swab was prognostic for CNSAC, six patients with CNSAC in our material had a negative swab. The two-swab procedure would therefore have reduced our CNSAC rate by one-third, leading to an even lower rate of CNSAC.
Our finding of almost identical rates of CNSAC in early systemic as well as in generalized GPA supports the validity of the rate of CNSAC in our material of 15.2%. This subset with CNSAC is therefore likely to reflect the rate of CNSAC in the background population. The original 
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The univariate Cox proportional hazards model was applied for the comparison of patients with chronic SA carriage vs other patients (intermittent carriers or noncarriers). In early systemic AAV patients, all medication was terminated at 12 months and the second hazard ratio (HR) is given including the first 12 months only.
finding that CNSAC involves a 7-fold risk for relapse probably reflects that their GPA patients were diagnosed 79 months (median) earlier and recruited from the outpatient clinic [5] . Their high rate (63%) of CNSAC could thus reflect accumulation of relapsing patients and/or patients with damaged nasal mucosa, necessitating frequent follow-up. Importantly, biopsy-proven nasal involvement was demonstrated in most cases of their relapses [5] . In our study with newly diagnosed patients, nasal disease activity was clinically suspected in only 48% of relapses. However, nasal biopsies at relapse were not required in SAVAS, which is a drawback of the present investigation, as it may be difficult to separate nasal infection from nasal disease activity on clinical examination only. This is also a general confounder when evaluating the role of infection for triggering relapse. The SAVAS protocol, however, was designed only as an add-on study to the primary therapeutic trials [13, 14] and was not designed specifically to investigate the effect of CNSAC or the correlation with nasal relapses.
In 77% of all our GPA patients, relapses occurred without CNSAC. This is partly attributable to the design of NORAM (early systemic GPA), with immunosuppression given during only the first 12 months, as the majority of relapses occurred during the 6 months after immunosuppression. These late relapses were not related to CNSAC and therefore constitute a confounder of the statistics when using the entire NORAM material.
The very low rate of CNSAC in newly diagnosed non-GPA patients (2%) was unexpected. These patients, primarily MPA patients, do not have nasal symptoms and do not develop granulomatous, destructive lesions in the ENT region. This would suggest a link between the lack of nasal symptoms and the low rate of CNASC in MPA. This could reflect subtle differences in genotypes of GPA and MPA corresponding to the genetic distinction between GPA, that is, mostly PR3-ANCA-positive patients, and MPA, that is, mostly MPO-ANCA-positive patients [23] .
Our observations that relapses also occur in GPA patients without positive SA swabs and that relapses occur even when CNSAC is prevented by prophylactic T/S treatment indicate that SA may play only a secondary pathogenic role, whereas the underlying phenotype of CNSAC may express genetically determined factors of primary pathogenic importance. This concept of a distinct genotype for GPA patients with CNSAC may be supported by two recent investigations reporting a disturbance of the nasal barrier at a genetic level and changes in the secretion of antimicrobial peptides in relationship to nasal SA colonization in GPA [24, 25] . Although the differentially expressed transcripts were reported to be independent of SA colonization in the entire material, identification of meaningful subphenotypes was suggested possibly to change this picture [24] .
Although T/S prophylaxis almost completely prevented CNSAC in the present study, this did not reduce relapses. In contrast, T/S reduced relapses by 66% in the Dutch RCT [8] . This might reflect the fact that the most frequent dosage used in the present study was a P. jirovecii prophylaxis dose (960 mg three times a week), whereas the Dutch study used a full dose, that is, 960 mg twice a day. Unfortunately, nasal SA carriage was not explored in the Dutch study [8] . The effect of the presence of SA on relapse is therefore still not clarified.
In conclusion, we have identified that the subset of GPA patients with CNSAC, which in newly diagnosed GPA patients reflect CNSAC in the background population, has an increased risk for relapse irrespective of disease severity, and being significantly different from MPA. We suggest that the increased relapse rate for this subset with CNSAC is not primarily attributable to the presence of SA but rather to genetically determined factors related to this phenotype. Although this subset of chronic SA carriers accounts for only 15% of GPA patients, these patients contribute half of the relapses for generalized disease during immunosuppressive treatment and therefore pose a serious challenge to identify additional treatment. We therefore propose that two nasal swabs are performed routinely during the diagnostic phase while the patients have not been on antibiotic treatment for at least a week, in order to identify chronic carriers [22] . The CNSAC patients may benefit from full-dose S/T treatment, but probably represent a genetic subset with individual and specific targets typical for CNSAC. The fact that they are seen very frequently in the outpatient clinics as chronic patients further adds to the importance of investigating the pathogenic mechanisms for this subset in order to develop new treatment strategies for these patients.
